Total views : 382

Role of Serum HIF-1alpha and VEGF-A as an Angiogenic Factors in Women with Heavy Menstrual Bleeding

Affiliations

  • Department of Biochemistry, Kasturba Medical College, Manipal University, Manipal - 576104, Karnataka, India
  • Melaka Manipal Medical College, Manipal University, Manipal – 576104, Karnataka, India
  • Department of Obstetrics and Gynecology, Kasturba Medical College, Manipal University, Manipal - 576104, Karnataka, India
  • Department of Community Medicine, Kasturba Medical College, Manipal University, Manipal - 576104, Karnataka, India

Abstract


Aim: The purpose of this study to evaluate the levels of potent angiogenic factors, such as VEGF-A (Vascular Endothelial Growth Factor-A) and HIF-1 alpha (Hypoxia Induced Factor) in patients with Heavy Menstrual Bleeding (HMB). In addition, serum copper and ceruloplasmin as modulator of angiogenesis were investigated. We evaluated haemoglobin concentration and ET (Endometrial Thickness) as clinical and laboratory features of disease to investigate role of angiogenesis in etiology of HMB. Methods/Analysis: This case-control study was conducted on 120 females aged between 22-48 years with history of bleeding excessively for more than 3 months and 120 control samples. 5 ml of blood sample was collected from HMB patients and controls. Serum HIF-1 alpha, VEGF-A were measured by ELISA kit method. Copper was estimated using 3,5-dibromo-2-pyridylazo-N-ethyl-N-3 sulphopropyl aniline. Ceruloplasmin was estimated using P-Phenylenediamine (PPD) oxidase method. Endometrial thickness was obtained from Ultrasonography (USG). Hemoglobin was estimated using Drabkin’s method. Findings: We observed higher concentration of VEGF-A as well as HIF-1 alpha in patient with HMB as compared to healthy women. The ROC (Receiver Operating Characteristic) curve was used to obtain optimal cutoff of VEGF-A as well as HIF-1 alpha to discriminate the HMB. Conclusion: Increase serum HIF-1alpha, VEGF-A and copper might be seen as predictors of HMB and increase efficacy of treatment.

Keywords

ET (Endometrial Thickness), HIF-1 Alpha (Hypoxia Induced Factor), HMB (Heavy Menstrual Bleeding), VEGF-A (Vascular Endothelial Growth Factor-A).

Full Text:

 |  (PDF views: 199)

References


  • Doraiswami S, Johnson T, Rao S, Rajkumar A, et al. Study of endometrial pathology in abnormal uterine bleeding. The Journal of Obstetrics and Gynecology of India. 2011; 61(4):426–30.
  • Harlow SD, Campbell OM. Epidemiology of menstrual disorders in developing countries: A systematic review. BJOG: An International Journal of Obstetrics and Gynaecology. 2004; 111(1):6–16.
  • Munro MG, Critchley HDD, et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. International Journal of Gynecology and Obstetrics, 2011; 113(1):3–13.
  • Cromwell DA, Mahmood TA, Templeton A, van der Meulen JH. Surgery for menorrhagia within English regions: Variation in rates of endometrial ablation and hysterectomy. BJOG. 2009; 116(10):1373–9.
  • Santer M, Warner P, Wyke S. A Scottish postal survey suggested that the prevailing clinical preoccupation with heavy periods does not reflect the epidemiology of reported symptoms and problems. J Clin Epidemiol. 2005; 58(11):1206–10.
  • Warner P, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray G. Referral for menstrual problems: Cross sectional survey of symptoms, reasons for referral, and management. Br Med J [Clin Res]. 2001; 323:24–8.
  • Gath D, Osborn M, Bungay G, Iles S, Day A, Bond A, et al. Psychiatric disorder and gynaecological symptoms in middle aged women: A community survey. Br Med J [Clin Res], 1987; 294(6566):213–8.
  • Gargett CE, Rogers PA. Human endometrial angiogenesis. Reproduction. 2001; 121(2):181–6.
  • Fukuda R, Kelly B, Semenza GL. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res. 2003; 63(9):2330–4.
  • Higgins DF, Biju MP, Akai Y, Wutz A, Johnson RS, Haase VH. Hypoxic induction of Ctgf is directly mediated by Hif-1. Am J Physiol Renal Physiol. 2004; 287(6):1223–32.
  • Semenza GL. HIF-1: Mediator of physiological and pathophysiological responses to hypoxia. Journal of Appl Physiol. 2000; 88(4):1474–80.
  • Critchley HO, Osei J, Henderson TA, Boswell L, Sales KJ, Jabbour HN, Hirani N. Hypoxia-inducible factor-1α expression in human endometrium and its regulation by prostaglandin E-series prostanoid receptor 2 (EP2). Endocrinology. 2006; 147(2):744–53.
  • Harris ED. A requirement for copper in angiogenesis. Nutrition Reviews. 2004; 62(2):60–4.
  • Chianeh YR, Rao P. Molecular and hormonal regulation of angiogenesis in proliferative endometrium. Int J Res Med Sci. 2014; 2(1):1–9.
  • Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM, Bias C, et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer research. 2002; 62(17):4854–9.
  • Yoshii J. The copper‐chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. International Journal of Cancer. 2001; 94(6):768–73.
  • Khandhadiya KP, Chianeh YR, Pragna R. Role of serum copper and ceruloplasmin level in patients with dysfunctional uterine bleeding. Int J Reprod Contracept Obstet Gynecol. 2014; 3(2):330–34.
  • Mints M, Blomgren B, Fqalconer C, et al. Microvascular density, vascular endothelial growth factor A, and its receptors in endometrial blood vessels in patients with menorrhagia. Fertility and Sterility. 2005; 84(3):692–700.
  • Sen CK, Khanna S, Venojarvi M, et al. Copper-induced vascular endothelial growth factor expression and wound healing. American Journal of Physiology-Heart and Circulatory Physiology. 2002; 282(5):1821–7.
  • Zhang L, Scott PA, Turley H, Leek R, Lewis CE, Gatter KC, Harris AL, Mackenzie IZ, Rees MC, Bicknell R. Validation of anti-vascular endothelial growth factor (anti-VEGF) antibodies for immunohistochemical localization of VEGF in tissue sections: Expression of VEGF in the human endometrium. J Pathol. 1998; 185(4):402–8.
  • Charnock-Jones DS, Sharkey AM, Rajput-Williams J, Burch D, Schofield JP, Fountain SA, Boocock CA, Smith SK. Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. Biol Reprod. 1993; 48(5):1120–8.
  • Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005; 69(Suppl 3):4–10.
  • Malik S, Day K, Perrault I, Charnock-Jones DS, Smith SK. Reduced levels of VEGF-A and MMP-2 and MMP-9 activity and increased TNF-α in menstrual endometrium and effluent in women with menorrhagia. Hum Reprod. 2006; 21(8):2158–66.
  • Fukuda R, Kelly B, Semenza GL. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res. 2003; 63(9):2330–4.
  • Sales KJ, List T, Boddy SC, Williams AR, Anderson RA, Naor Z, Jabbour HN. A novel angiogenic role for prostaglandin F2α-FP receptor interaction in human endometrial adenocarcinomas. Cancer Res. 2005; 65:7707–16.
  • Higgins DF, Biju MP, Akai Y, Wutz A, Johnson RS, Haase VH. Hypoxic induction of Ctgf is directly mediated by Hif-1. Am J Physiol Renal Physiol. 2004; 287(6):1223–32.
  • Hänze J, Weissmann N, Grimminger F, Seeger W, Rose F. Cellular and molecular mechanisms of hypoxia-inducible factor driven vascular remodeling. Thromb Haemost. 2007; 97(5):774–87.
  • Critchley HO, Osei J, Henderson TA, Boswell L, Sales KJ, Jabbour HN, Hirani N. Hypoxia-inducible factor-1α expression in human endometrium and its regulation by prostaglandin E-series prostanoid receptor 2 (EP2). Endocrinology. 2006; 147(2):744–53.
  • Mizukami Y, Li J, Zhang X, Zimmer MA, Iliopoulos O, Chung DC. Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res. 2004; 64(5):1765–72.

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.